Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 11, 2019. The document serves as a transaction notification regarding insider trading activity rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to disclosing a specific securities transaction.
Material Changes and Transaction Details
The filing discloses a sale of ordinary shares by a person closely associated with a Principal Director or Manager (PDMR). The specific details are as follows:
- Transaction Type: Sale of Ordinary Shares (25 pence each).
- Instrument ISIN: GB0009252882.
- Transaction Date: February 8, 2019.
- Place of Transaction: London Stock Exchange (XLON).
- Volume: 23,205 shares.
- Price: £15.5429 per share.
- Related Party: Mrs. D. Connor, identified as a PCA of Mr. R. G. Connor (President, Global Vaccines).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of a share sale.
Investor Verification Checklist
- Verify the identity of the seller (Mrs. D. Connor) and her relationship to the PDMR (Mr. R. G. Connor).
- Confirm the transaction price (£15.5429) against the market price on February 8, 2019.
- Check subsequent filings to determine if this transaction was part of a larger divestment plan or a routine portfolio adjustment.
- Review the company's latest Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial metrics.